Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine
Multicenter, Randomized, Blind, Placebo-controlled Clinical Study of III Phase on Assessment of Preventive Efficiency, Safety and Immunogenicity QazCovid-in®-Vaccine Against COVID-19 in Healthy Adult Volunteers
Sponsor: City Multidisciplinary Hospital of Zhambyl Region Ministry of Healthcare of the Republic of Kazakhstan
A PHASE3 clinical study on Covid19 and SARS-CoV Infection, this trial is completed. The trial is conducted by City Multidisciplinary Hospital of Zhambyl Region Ministry of Healthcare of the Republic of Kazakhstan and has accumulated 7 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jan 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 2 earlier versions
-
Mar 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Enrolling By Invitation PHASE3
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- City Multidisciplinary Hospital of Zhambyl Region Ministry of Healthcare of the Republic of Kazakhstan
- City polyclinic No. 4 of the of Almaty Ministry of Healthcare of the Republic of Kazakhstan
- Clinic of the International Institute of Postgraduate Education Ministry of Healthcare of the Republic of Kazakhstan
- Research Institute for Biological Safety Problems
For direct contact, visit the study record on ClinicalTrials.gov .